Back to Clinical Trials
Phase 1Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Sponsored by Eli Lilly and Company

About this study

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Where this study is enrolling (2)

  • Emory University School of Medicine

    Atlanta, Georgia

    I'm interested

  • MD Anderson Cancer Center

    Houston, Texas

    Call 877-632-6789

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • ✓Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
  • ✓Have an ECOG performance status of ≤ 1
  • ✓Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease
  • ✓Participants with asymptomatic or treated CNS disease may be eligible.

Exclusion criteria

  • ✕Have known active CNS metastases and/or carcinomatous meningitis.
  • ✕Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.
  • ✕Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.
  • ✕Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
  • ✕Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).
  • ✕Have other active malignancy unless in remission with life expectancy greater than (\>) 2 years.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.